Sensitivity–Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration
暂无分享,去创建一个
C. Jack | M. Filippi | M. Senjem | V. Lowe | S. Weigand | C. Schwarz | M. Murray | D. Dickson | J. Parisi | J. Duffy | J. Whitwell | M. Baker | K. Josephs | M. Machulda | H. Botha | N. Tosakulwong | A. Spychalla | H. Clark | R. Utianski | F. Ali | N. Pham | M. Buciuc | S. Labuzan | Alma Ghirelli | R. Rademakers | Marina Buciuc | Farwa Ali | Nirubol Tosakulwong
[1] V. Lowe,et al. In Vivo Imaging and Autoradiography in a Case of Autopsy-Confirmed Pick Disease. , 2019, Neurology. Clinical practice.
[2] John L. Robinson,et al. Primary Tau Pathology, Not Copathology, Correlates With Clinical Symptoms in PSP and CBD. , 2019, Journal of neuropathology and experimental neurology.
[3] Barbara Borroni,et al. Faculty Opinions recommendation of 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes. , 2019 .
[4] David T. Jones,et al. Tau-positron emission tomography correlates with neuropathology findings , 2019, Alzheimer's & Dementia.
[5] David T. Jones,et al. The bivariate distribution of amyloid-β and tau: relationship with established neurocognitive clinical syndromes , 2019, Brain : a journal of neurology.
[6] David T. Jones,et al. Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease , 2019, Alzheimer's & Dementia.
[7] K. Ishii,et al. Characterization of the binding of tau imaging ligands to melanin-containing cells: putative off-target-binding site , 2019, Annals of Nuclear Medicine.
[8] Peter R. Martin,et al. The influence of β-amyloid on [18F]AV-1451 in semantic variant of primary progressive aphasia , 2019, Neurology.
[9] Maria Luisa Gorno-Tempini,et al. 18F-flortaucipir (AV-1451) tau PET in frontotemporal dementia syndromes , 2019, Alzheimer's Research & Therapy.
[10] C. Jack,et al. Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology , 2018, Alzheimer's & Dementia.
[11] Peter R. Martin,et al. [18F]AV‐1451 tau‐PET and primary progressive aphasia , 2018, Annals of neurology.
[12] Peter R. Martin,et al. [18F] AV-1451 uptake in corticobasal syndrome: the influence of beta-amyloid and clinical presentation , 2018, Journal of Neurology.
[13] Rene L. Utianski,et al. Tau-PET imaging with [18F]AV-1451 in primary progressive apraxia of speech , 2018, Cortex.
[14] Siobhan Ewert,et al. Toward defining deep brain stimulation targets in MNI space: A subcortical atlas based on multimodal MRI, histology and structural connectivity , 2016, NeuroImage.
[15] C. Jack,et al. Pittsburgh Compound B and AV-1451 positron emission tomography assessment of molecular pathologies of Alzheimer's disease in progressive supranuclear palsy. , 2018, Parkinsonism & related disorders.
[16] Jesse A. Brown,et al. Clinicopathological correlations in behavioural variant frontotemporal dementia , 2017, Brain : a journal of neurology.
[17] Luca Passamonti,et al. [18F]AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2017, Journal of Neurology, Neurosurgery, and Psychiatry.
[18] Hanna Cho,et al. 18F-AV-1451 binds to motor-related subcortical gray and white matter in corticobasal syndrome , 2017, Neurology.
[19] Victor L. Villemagne,et al. Assessment of amyloid β in pathologically confirmed frontotemporal dementia syndromes , 2017, Alzheimer's & dementia.
[20] David T. Jones,et al. Defining imaging biomarker cut points for brain aging and Alzheimer's disease , 2017, Alzheimer's & Dementia.
[21] Luca Passamonti,et al. 18F-AV-1451 positron emission tomography in Alzheimer’s disease and progressive supranuclear palsy , 2017, Brain : a journal of neurology.
[22] Hanna Cho,et al. Subcortical 18F‐AV‐1451 binding patterns in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[23] Anthony J. Spychalla,et al. [18F]AV‐1451 tau positron emission tomography in progressive supranuclear palsy , 2017, Movement disorders : official journal of the Movement Disorder Society.
[24] Sang Won Seo,et al. Regional correlations between [11C]PIB PET and post-mortem burden of amyloid-beta pathology in a diverse neuropathological cohort , 2016, NeuroImage: Clinical.
[25] M. Schain,et al. Increased basal ganglia binding of 18 F‐AV‐1451 in patients with progressive supranuclear palsy , 2016, Movement disorders : official journal of the Movement Disorder Society.
[26] Young T. Hong,et al. 18 FAV-1451 positron emission tomography in Alzheimer ’ s disease and progressive supranuclear palsy , 2017 .
[27] J. Trojanowski,et al. Multimodal evaluation demonstrates in vivo 18F-AV-1451 uptake in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[28] Nick C Fox,et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias , 2016, Alzheimer's & Dementia.
[29] C. Jack,et al. [18F]AV-1451 tau-PET uptake does correlate with quantitatively measured 4R-tau burden in autopsy-confirmed corticobasal degeneration , 2016, Acta Neuropathologica.
[30] Clifford R. Jack,et al. An autoradiographic evaluation of AV-1451 Tau PET in dementia , 2016, Acta Neuropathologica Communications.
[31] Keith A. Johnson,et al. Validating novel tau positron emission tomography tracer [F‐18]‐AV‐1451 (T807) on postmortem brain tissue , 2015, Annals of neurology.
[32] Clifford R. Jack,et al. Clinicopathologic and 11C-Pittsburgh compound B implications of Thal amyloid phase across the Alzheimer’s disease spectrum , 2015, Brain : a journal of neurology.
[33] Janna H. Neltner,et al. Primary age-related tauopathy (PART): a common pathology associated with human aging , 2014, Acta Neuropathologica.
[34] H. Shill,et al. Concomitant pathologies among a spectrum of parkinsonian disorders. , 2014, Parkinsonism & related disorders.
[35] H. Kolb,et al. [18F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease , 2013, Alzheimer's & Dementia.
[36] L. Ferrucci,et al. Correspondence between in vivo 11C-PiB-PET amyloid imaging and postmortem, region-matched assessment of plaques , 2012, Acta Neuropathologica.
[37] J. Schneider,et al. National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.
[38] Dennis W. Dickson,et al. Neuropathology of Frontotemporal Lobar Degeneration-Tau (FTLD-Tau) , 2011, Journal of Molecular Neuroscience.
[39] J. Trojanowski,et al. A harmonized classification system for FTLD-TDP pathology , 2011, Acta Neuropathologica.
[40] Charles Duyckaerts,et al. National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.
[41] B. Boeve,et al. Does TDP-43 type confer a distinct pattern of atrophy in frontotemporal lobar degeneration? , 2010, Neurology.
[42] D. Dickson,et al. Cortical Alzheimer type pathology does not influence tau pathology in progressive supranuclear palsy. , 2009, International journal of clinical and experimental pathology.
[43] Nancy Johnson,et al. Alzheimer and frontotemporal pathology in subsets of primary progressive aphasia , 2008, Annals of neurology.
[44] Karl J. Friston,et al. Unified segmentation , 2005, NeuroImage.
[45] D. Dickson,et al. Apolipoprotein E epsilon 4 is a determinant for Alzheimer-type pathologic features in tauopathies, synucleinopathies, and frontotemporal degeneration. , 2004, Archives of neurology.
[46] W. Klunk,et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.
[47] H. Braak,et al. Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.
[48] P. Lantos,et al. Office of Rare Diseases Neuropathologic Criteria for Corticobasal Degeneration , 2002, Journal of neuropathology and experimental neurology.
[49] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[50] D. Dickson. Neuropathology of Pick’s disease , 2001, Neurology.
[51] S. M. Sumi,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.
[52] Z. Khachaturian. Diagnosis of Alzheimer's disease. , 1985, Archives of neurology.
[53] Young T. Hong,et al. AV-1451 binding in vivo mirrors the expected distribution of TDP-43 pathology in the semantic variant of primary progressive aphasia , 2022 .